Literature DB >> 9345067

Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells.

F T Hakim1, R Cepeda, S Kaimei, C L Mackall, N McAtee, J Zujewski, K Cowan, R E Gress.   

Abstract

To examine the mechanisms of CD4 reconstitution in an adult population, lymphocyte repopulation was assessed following dose-intense chemotherapy in 25 breast cancer patients, ages 33 to 69 years. Chemotherapy resulted in a greater than 60% reduction in total CD4 T cells and, in particular, a greater than 90% loss of the CD45RA+ CD4 cells. CD4 recovery was protracted, achieving less than 50% of pretreatment levels after 12 to 14 months. Two facets of the CD4 recovery were notable. First, generation of CD45RA+ CD4 cells played only a minor role in the first year, suggesting that thymic production was not the main route of CD4 regeneration. Indeed, recovery of CD45RA+ CD4 cell levels remained limited in half of the patients even after 2 years. Second, expansion of the mature peripheral CD4 cells (CD45RO+) remaining after chemotherapy was the main source of early CD4 repopulation, peaking at 3 to 6 months postchemotherapy. This expansion was limited in duration, however, and was followed by a secondary decline, such that the total CD45RO+ CD4 levels at 9 to 12 months were lower than at 6 months. When stimulated by mitogens, an increased susceptibility to apoptosis was observed in postchemotherapy CD4 cells as compared with those from normal donors. The elevated expression of markers such as HLA-DR during chemotherapy and for several months postchemotherapy is consistent with the presence of an activated T-cell population. CD4 apoptotic frequency correlated with the frequency of HLA-DR expression on T cells. Thus, CD4 recovery is constrained in adults by a limited thymic regenerative capacity and by an increased susceptibility to apoptosis within the expanding peripheral CD4 population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9345067

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  70 in total

1.  Homeostatic proliferation is a barrier to transplantation tolerance.

Authors:  Zihao Wu; Steven J Bensinger; Jidong Zhang; Chuangqi Chen; Xueli Yuan; Xiaolun Huang; James F Markmann; Alireza Kassaee; Bruce R Rosengard; Wayne W Hancock; Mohamed H Sayegh; Laurence A Turka
Journal:  Nat Med       Date:  2003-11-30       Impact factor: 53.440

2.  Homeostatic expansion and phenotypic conversion of human T cells depend on peripheral interactions with APCs.

Authors:  Takashi Onoe; Hannes Kalscheuer; Meredith Chittenden; Guiling Zhao; Yong-Guang Yang; Megan Sykes
Journal:  J Immunol       Date:  2010-05-10       Impact factor: 5.422

Review 3.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

4.  Age-dependent incidence, time course, and consequences of thymic renewal in adults.

Authors:  Frances T Hakim; Sarfraz A Memon; Rosemarie Cepeda; Elizabeth C Jones; Catherine K Chow; Claude Kasten-Sportes; Jeanne Odom; Barbara A Vance; Barbara L Christensen; Crystal L Mackall; Ronald E Gress
Journal:  J Clin Invest       Date:  2005-03-17       Impact factor: 14.808

5.  Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation.

Authors:  Ursula Hainz; Petra Obexer; Christiana Winkler; Peter Sedlmayr; Osamu Takikawa; Hildegard Greinix; Anita Lawitschka; Ulrike Pötschger; Dietmar Fuchs; Stephan Ladisch; Andreas Heitger
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

6.  B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.

Authors:  Kieron Dunleavy; Frances Hakim; Hyun Kyung Kim; John E Janik; Nicole Grant; Takayuki Nakayama; Therese White; George Wright; Larry Kwak; Ronald Gress; Giovanna Tosato; Wyndham H Wilson
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

Review 7.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Lung cancer in HIV infected patients: facts, questions and challenges.

Authors:  J Cadranel; D Garfield; A Lavolé; M Wislez; B Milleron; C Mayaud
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

9.  The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Authors:  Il-Kang Na; Sydney X Lu; Nury L Yim; Gabrielle L Goldberg; Jennifer Tsai; Uttam Rao; Odette M Smith; Christopher G King; David Suh; Daniel Hirschhorn-Cymerman; Lia Palomba; Olaf Penack; Amanda M Holland; Robert R Jenq; Arnab Ghosh; Hien Tran; Taha Merghoub; Chen Liu; Gregory D Sempowski; Melissa Ventevogel; Nicole Beauchemin; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

10.  IL-15 trans-presentation regulates homeostasis of CD4(+) T lymphocytes.

Authors:  Xi-Lin Chen; Diwakar Bobbala; Yuneivy Cepero Donates; Marian Mayhue; Subburaj Ilangumaran; Sheela Ramanathan
Journal:  Cell Mol Immunol       Date:  2014-03-24       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.